Cathepsin B: a potential prognostic marker for inflammatory breast cancer
2011

Cathepsin B as a Prognostic Marker for Inflammatory Breast Cancer

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): Nouh Mohamed A, Mohamed Mona M, El-Shinawi Mohamed, Shaalan Mohamed A, Cavallo-Medved Dora, Khaled Hussein M, Sloane Bonnie F

Primary Institution: National Cancer Institute, Cairo University

Hypothesis

Is cathepsin B a potential prognostic marker for inflammatory breast cancer?

Conclusion

Cathepsin B may serve as a potential prognostic marker for lymph node metastasis in inflammatory breast cancer.

Supporting Evidence

  • CTSB and cav-1 were overexpressed in IBC compared to non-IBC tissues.
  • There was a significant positive correlation between CTSB expression and the number of positive metastatic lymph nodes in IBC.
  • IBC patients were significantly younger at diagnosis compared to non-IBC patients.

Takeaway

This study found that a protein called cathepsin B is more active in a dangerous type of breast cancer, which might help doctors predict how likely it is to spread.

Methodology

The study involved 23 inflammatory breast cancer patients and 27 non-inflammatory breast cancer patients, analyzing tissue samples for cathepsin B and caveolin-1 expression using immunohistochemistry and immunoblotting.

Potential Biases

Potential biases may arise from the selection of patients and the retrospective nature of the study.

Limitations

The study was limited to a small sample size and specific patient demographics.

Participant Demographics

IBC patients aged 29-60 years (mean age 40.9), non-IBC patients aged 33-67 years (median age 49.9).

Statistical Information

P-Value

0.0478

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-9-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication